Cargando…

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization

Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization....

Descripción completa

Detalles Bibliográficos
Autores principales: Parks, K. Rachael, MacCamy, Anna J., Trichka, Josephine, Gray, Matthew, Weidle, Connor, Borst, Andrew J., Khechaduri, Arineh, Takushi, Brittany, Agrawal, Parul, Guenaga, Javier, Wyatt, Richard T., Coler, Rhea, Seaman, Michael, LaBranche, Celia, Montefiori, David C., Veesler, David, Pancera, Marie, McGuire, Andrew, Stamatatos, Leonidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936959/
https://www.ncbi.nlm.nih.gov/pubmed/31801073
http://dx.doi.org/10.1016/j.celrep.2019.10.071
_version_ 1783483793297899520
author Parks, K. Rachael
MacCamy, Anna J.
Trichka, Josephine
Gray, Matthew
Weidle, Connor
Borst, Andrew J.
Khechaduri, Arineh
Takushi, Brittany
Agrawal, Parul
Guenaga, Javier
Wyatt, Richard T.
Coler, Rhea
Seaman, Michael
LaBranche, Celia
Montefiori, David C.
Veesler, David
Pancera, Marie
McGuire, Andrew
Stamatatos, Leonidas
author_facet Parks, K. Rachael
MacCamy, Anna J.
Trichka, Josephine
Gray, Matthew
Weidle, Connor
Borst, Andrew J.
Khechaduri, Arineh
Takushi, Brittany
Agrawal, Parul
Guenaga, Javier
Wyatt, Richard T.
Coler, Rhea
Seaman, Michael
LaBranche, Celia
Montefiori, David C.
Veesler, David
Pancera, Marie
McGuire, Andrew
Stamatatos, Leonidas
author_sort Parks, K. Rachael
collection PubMed
description Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies.
format Online
Article
Text
id pubmed-6936959
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-69369592019-12-30 Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization Parks, K. Rachael MacCamy, Anna J. Trichka, Josephine Gray, Matthew Weidle, Connor Borst, Andrew J. Khechaduri, Arineh Takushi, Brittany Agrawal, Parul Guenaga, Javier Wyatt, Richard T. Coler, Rhea Seaman, Michael LaBranche, Celia Montefiori, David C. Veesler, David Pancera, Marie McGuire, Andrew Stamatatos, Leonidas Cell Rep Article Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies. 2019-12-03 /pmc/articles/PMC6936959/ /pubmed/31801073 http://dx.doi.org/10.1016/j.celrep.2019.10.071 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Parks, K. Rachael
MacCamy, Anna J.
Trichka, Josephine
Gray, Matthew
Weidle, Connor
Borst, Andrew J.
Khechaduri, Arineh
Takushi, Brittany
Agrawal, Parul
Guenaga, Javier
Wyatt, Richard T.
Coler, Rhea
Seaman, Michael
LaBranche, Celia
Montefiori, David C.
Veesler, David
Pancera, Marie
McGuire, Andrew
Stamatatos, Leonidas
Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title_full Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title_fullStr Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title_full_unstemmed Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title_short Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
title_sort overcoming steric restrictions of vrc01 hiv-1 neutralizing antibodies through immunization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936959/
https://www.ncbi.nlm.nih.gov/pubmed/31801073
http://dx.doi.org/10.1016/j.celrep.2019.10.071
work_keys_str_mv AT parkskrachael overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT maccamyannaj overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT trichkajosephine overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT graymatthew overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT weidleconnor overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT borstandrewj overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT khechaduriarineh overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT takushibrittany overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT agrawalparul overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT guenagajavier overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT wyattrichardt overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT colerrhea overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT seamanmichael overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT labranchecelia overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT montefioridavidc overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT veeslerdavid overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT panceramarie overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT mcguireandrew overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization
AT stamatatosleonidas overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization